Dynamazin®

Dosage form Application area Recommendations for use Contraindications Manufacturer
Read on
Certificate number:RU.77.99.11.003.Е.001476.04.16
Date of registration and renewal:04.04.2016
Dosage form: & nbsp
Tableti with a mass of 1520 mg
Classification "Composition" & nbsp Dietary supplements - proteins, amino acids and their derivatives BAD - vitamin and mineral complexes
Classification "Clinical" & nbsp BAD-sources of multivitamins containing individual minerals and mineral complexes BAA sources of amino acids
Composition: & nbspAscorbic acid, nicotinomide, vitamin E acetate, calcium D-pantothenate, pyridoxine hydrochloride, riboflavin, thiamine mononitrate, vitamin A palminate, biotin, vitamin D3, vitamin B12, calcium phosphate b / w granular, magnesium oxide, zinc oxide, manganese sulfate monohydrate, copper hydrogencarbonate, potassium iodide, sodium selenate, sodium molybdate dihydrate, chromium chloride hexahydrate, arginine monohydrochloride, L-glutamine, dry extract of common gum, E551, E471, E468, E470b, E464, E1201, E421, E460i, E570, E171, E172 .
Scope: & nbspFor sale to the population through the pharmacy network and specialized stores, the sales network departments as a biologically active food additive - an additional source of vitamins, macro- and microelements, a source of panaxosides containing glutamine.
Suggested Usage: & nbspAdults from 18 years of age take 1 tablet in the morning during meals. Duration of admission is 2-3 weeks. If necessary, the reception can be repeated within a year. Before use, it is recommended to consult a doctor.
Contraindications:Individual intolerance of components, pregnancy, breast-feeding, increased nervous excitability, insomnia, hypertension, cardiac dysfunction, severe atherosclerosis.
Special instructions:Persons with thyroid disease are advised to consult an endocrinologist.
Shelf life:2 years.
Storage conditions:Keep out of the reach of children at a temperature of no higher than 25 ° C.
Research protocols:In exchange for the certificate of state registration No. RU.77.99.11.003.Е.006148.04.15 of 30.04.2015, the expert opinion of the FGBM of the Federal Targeted Register and the Federal Service for Consumer Rights Protection No. 10-2FTS / 1048 of 26.02.2015.
Recipient:GlaxoSmithKline Helsker, AOGlaxoSmithKline Helsker, AO Russian Federation
Information update date: & nbsp07.01.2017
Instructions
Up